PCOS and Weight Loss in Australia: How GLP-1 Medications Are Changing the Picture
Key Takeaways
PCOS creates a genuine biological barrier to weight loss. GLP-1 medications are now available in Australia and are showing real promise for women with PCOS — here's what the evidence says.
Why PCOS Makes Weight Loss Harder — and Why GLP-1 Medications Change That
If you have polycystic ovary syndrome (PCOS) and you've struggled to lose weight despite doing everything your doctor told you — eating less, exercising more, cutting carbs — you are not imagining it. PCOS creates a genuine biological barrier to weight loss that goes well beyond willpower, and for decades there were very limited medical options to address it.
That has changed significantly in the past few years. GLP-1 receptor agonist medications, particularly semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have become available in Australia and are now being used — with increasing evidence — to address both the weight and the metabolic drivers of PCOS simultaneously.
This guide explains why PCOS complicates weight management, what the research shows about GLP-1 medications for PCOS specifically, and how Australian women can access this treatment.
Why PCOS Makes Weight Loss Biologically Harder
PCOS affects approximately 1 in 10 Australian women of reproductive age. It is not just a reproductive condition — it is a complex metabolic disorder with several features that directly impede weight management:
Insulin Resistance
Between 50–70% of women with PCOS have insulin resistance — a condition where cells don't respond normally to insulin, causing the pancreas to produce more of it. Elevated insulin levels promote fat storage (particularly abdominal fat), increase hunger, and drive carbohydrate cravings. This creates a cycle that makes caloric restriction difficult to sustain.
Hyperandrogenism
Elevated androgens (male hormones) in PCOS contribute to a body fat distribution pattern that favours visceral (abdominal) fat accumulation. Visceral fat is metabolically active and associated with further insulin resistance — creating another reinforcing cycle.
Disrupted Appetite Hormones
Research has found that women with PCOS have altered levels of appetite-regulating hormones including ghrelin, leptin, and GLP-1 itself — meaning the body's natural satiety signalling is impaired. This is not a lack of willpower; it is an endocrine dysfunction.
Reduced Resting Metabolic Rate
Some studies suggest women with PCOS may have a lower resting metabolic rate than women without PCOS at the same weight — meaning the same caloric restriction produces less weight loss.
Have PCOS and struggling with weight?
Our GPs understand the metabolic and hormonal drivers of PCOS. Get a bulk billed telehealth assessment — no referral required.
What Does the Research Show About GLP-1 Medications for PCOS?
The evidence base for GLP-1 medications specifically in PCOS is growing rapidly, though much of it is still emerging. Here is what the current data shows:
Weight Loss
Clinical trials and real-world evidence consistently show that women with PCOS achieve significant weight loss on semaglutide and tirzepatide — comparable to or exceeding the general population results. Given that PCOS makes weight loss harder through conventional means, this is significant.
Insulin Resistance Improvement
GLP-1 medications directly address insulin resistance — one of the core metabolic drivers of PCOS. Studies have shown meaningful improvements in HOMA-IR (a measure of insulin resistance) and fasting insulin levels in PCOS patients on semaglutide.
Androgen Reduction
Several studies have found reductions in free and total testosterone levels in women with PCOS taking GLP-1 medications. Lower androgens may improve symptoms including hirsutism, acne, and irregular menstrual cycles.
Menstrual Regularity
Weight loss of as little as 5–10% can restore or improve menstrual regularity in women with PCOS. Given that GLP-1 medications typically produce well above this threshold, improvements in cycle regularity are a commonly reported outcome.
Fertility
Improved metabolic health, reduced androgens, and restored ovulation may improve fertility in women with PCOS. This is an area of active research. Importantly, these medications must be stopped before conception — discuss this with your GP if pregnancy is a consideration.
Is GLP-1 Treatment Appropriate for Every Woman with PCOS?
No — and this is where individual clinical assessment matters. GLP-1 medications are generally considered for women with PCOS who:
- Have a BMI ≥ 30, or BMI ≥ 27 with PCOS-related comorbidities (insulin resistance, type 2 diabetes, hypertension)
- Have not achieved adequate results through diet, exercise, and where appropriate, metformin
- Are not currently pregnant or planning pregnancy in the immediate term
- Do not have contraindications to GLP-1 medications
Metformin remains a commonly used first-line medication for PCOS with insulin resistance in Australia, and may be used alongside GLP-1 medications in some patients.
How to Access GLP-1 Treatment for PCOS in Australia
Any Australian GP can assess and prescribe GLP-1 medications for eligible patients — you do not need a referral to an endocrinologist or gynaecologist first, though some complex cases may be referred on.
Telehealth consultations are a legitimate and widely used access pathway. Weight Loss GP Australia offers bulk billed telehealth consultations for eligible patients across all Australian states. Our GPs are experienced in assessing weight management in the context of PCOS and can discuss whether Ozempic, Wegovy, or Mounjaro is appropriate for your specific situation.
PCOS and weight loss support from an Australian GP.
Our GPs are experienced in the metabolic and hormonal challenges of PCOS. Bulk billed telehealth — request an appointment today.
Book a Consultation
